While it is likely that the ongoing trials of combinations of KRASG12C inhibitors with immunotherapies will be beneficial for a subset of KRAS-mutant NSCLC patients, this study has highlighted the need for additional treatment strategies in highly immune refractory patients. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.